title: [Cytoreductive surgery and HIPEC: a curative strategy for primary and secondary peritoneal tumors].
abstract: In patients with peritoneal carcinomatosis, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) offers a chance for long term survival in well selected patients. During cytoreductive surgery, all macroscopically visible tumors needs to be resected before HIPEC is performed in the same procedure. The aim of HIPEC is eradication of microscopic tumor cells after radical surgery. Perioperative morbidity and mortality are comparable with other major surgical procedures. Patients with peritoneal carcinomatosis from tumors of the appendix, the colon or primary peritoneal mesothelioma are currently recommended for evaluation of CRS/HIPEC in an interdisciplinary setting.
authors.affiliation: Klinik für Viszeral- und Transplantationschirurgie, Universitätsspital Zürich. kuno.lehmann@usz.ch
authors.forename: Kuno
authors.initials: K
authors.lastname: Lehmann
authors.forename: Philippe
authors.initials: P
authors.lastname: Gertsch
authors.forename: René
authors.initials: R
authors.lastname: Vonlanthen
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D017024:Chemotherapy, Adjuvant; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000295:instrumentation; D003131:Combined Modality Therapy; D006801:Humans; D007263:Infusions, Parenteral / Q000295:instrumentation; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary* / Q000601:surgery*